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and surgical drainage (52.8%), followed by 
mechanical ventilation (50.9%), and hemo-
dialysis (5.7%). Mean duration of hospital 
stay before the onset of bacteremia was 15 
days. Twenty-one of the 53 (40%) patients 
were in the ICU at the time of AB onset, and 
the mean duration of ICU stay before the 
onset of bacteremia was eight days. Diabetes 
mellitus (24.5%) was the most common un-
derlying disease, followed by chronic renal 
failure (17.0%), chronic obstructive pulmo-
nary disease (11.3%), congestive heart fail-
ure (CHF) (11.3%), and chronic liver dis-
ease (7.5%). Compared with the AB patients 
who survived, those who died had more 
A. baumannii complex and A. Iwoffii as the 
infecting species, increased use of mechani-
cal ventilation, prior use of central venous 
catheterization, longer duration of hospital 
and ICU stay before bacteremia onset, CHF 
as underlying disease, infusion of total par-
enteral nutrition and septic shock. Statisti-
cally significant association was found only 
with longer duration of hospital stay before 
bacteremia onset in a multivariate logistic 
regression model (odds ratio, 1.069; 95% CI, 
1.002–1.140; p = 0.042).
The mortality rate of AB in this study 
was 26.4% (14 cases), which is comparable 
to other studies (17-52%).4 A recent retro-
spective study showed that patients with 
MDR A. baumannii bacteremia had a high-
er mortality rate and longer hospital stays 
compared to those with non-MDR AB.5 
Our study revealed that a longer duration of 
hospital stay before bacteremia onset is the 
risk factor that leads to increased mortality. 
Although a retrospective study lowers the 
reliability of the conclusion that part of 
the mortality was directly attributable to 
longer duration of hospital stay, the impact 
of these issue is undeniable. At present, the 
rate of development of new drugs against 
Dear Editor,
Acinetobacter (AB) species are non-fer-
menting aerobic Gram-negative bacteria 
that have emerged as important nosocomial 
pathogens1 and multidrug resistant (MDR) 
Acinetobacter strains have increased rap-
idly.2 Moreover Acinetobacter bacteremia 
(AB) is associated with high mortality rates 
that vary from 17-52%. Although studies 
have been performed to reveal risk fac-
tors that affect MDR or pandrug-resistant 
(PDR) strains,3 the risk factor of mortality 
of patients with AB is yet unclear. With this 
in mind, the present study was undertaken 
to identify the risk factors associated with 
the mortality of AB patients.
A retrospective cohort study identifying 
risk factors for mortality in patients with 
AB between January 2007 and October 2009 
was performed at the Eulji Medical Center, 
a 1053-bed tertiary hospital in Daejeon, 
South Korea. Demographic, clinical, and 
laboratory variables were collected. For sta-
tistical analyses the SPSS software was used 
[95% confidence interval (CI), significant 
p-value < 0.05].
Fifty-three adult patients (30 males, 23 
females) with AB were included. The mean 
age of all patients was 63 years. Acinetobac-
ter baumannii complex was the most com-
mon isolate (76%), followed by Acinetobac-
ter lwoffii (21%), and Acinetobacter junii 
(4%). The antibiograms showed all-sensi-
tive susceptibility in 19% of the isolates, car-
bapenem resistance in 28%, MDR in 60%, 
and PDR in 8%. Fourteen patients (26.4%) 
received appropriate use of antibiotics. Un-
known site of bacteremia (69.8%) was the 
most frequent source of infection, followed 
by lung (28.3%), urinary tract (3.8%), wound 
(3.8%), and biliary tract (1.9%). The most 
common procedure before the onset of AB 
was central venous catheterization (52.8%) 
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MDR/PDR bacteria under-paces the rate of resistance 
development. So, preventive measures, such as dimin-
ishing the duration of hospital stay to avoid harmful 
bacteria are essential. Further studies are needed to ad-
dress the prevention and the appropriate use of antimi-
crobial agents in AB patients. 
Table 1. Multivariate analysis of risk factors for mortality in Acinetobacter bacteremia
 p-value Odds ratio 95% CI
Mechanical	ventilation	 0.908	 0.856	 0.060-12.173
Central	venous	catheterization	 0.885	 0.844	 0.085-8.344
Duration	of	hospital	stay	before	bacteremia	onset	 0.042	 1.069	 1.002-1.140
ICU	stay	at	time	of	bacteremia	onset	(%)	 0.076	 9.435	 0.792-112.447
MDR/PDR	 0.583	 0.546	 0.063-4.729
ICU, intensive care unit; MDR, multidrug resistance; PDR, pandrug resistance.
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